Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023.

Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024.

Since the announcement 19 February 2024, the following transactions have been made:

  Number ofB shares Averagepurchase price Transactionvalue, DKK
Accumulated, last announcement 394,500   327,673,060
19 February 2024 42,500 855.91 36,376,128
20 February 2024 43,000 855.39 36,781,829
21 February 2024 43,000 829.84 35,683,110
22 February 2024 43,000 848.41 36,481,707
23 February 2024 43,000 852.72 36,667,168
Accumulated under the programme 609,000   509,663,002

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 47,149,707 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,510,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 23 February 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 609,000 B shares at an average share price of DKK 836.89 per B share equal to a transaction value of DKK 509,663,002.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contact for further information

Media:  
Ambre James-Brown +45 3079 9289abmo@novonordisk.com Liz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com
Investors:  
Daniel Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com Mark Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com
Sina Meyer +45 3079 6656azey@novonordisk.com Frederik Taylor Pitter +45 3075 8259fptr@novonordisk.com

Company announcement No 18/2024

Attachments

  • 20240226 Safe Harbour CA
  • 20240226 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Novo Nordisk Charts.